Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | OLMA |
---|---|---|
09:32 ET | 5659 | 14.98 |
09:34 ET | 1255 | 14.84 |
09:36 ET | 2099 | 15.09 |
09:38 ET | 1685 | 15.38 |
09:39 ET | 1261 | 15.3291 |
09:41 ET | 1746 | 15.43 |
09:43 ET | 400 | 15.36 |
09:45 ET | 700 | 15.37 |
09:48 ET | 786 | 15.27 |
09:50 ET | 400 | 15.37 |
09:52 ET | 600 | 15.375 |
09:54 ET | 332 | 15.48 |
09:56 ET | 600 | 15.375 |
09:59 ET | 1204 | 15.27 |
10:01 ET | 300 | 15.3 |
10:03 ET | 296 | 15.305 |
10:06 ET | 100 | 15.23 |
10:08 ET | 500 | 15.225 |
10:10 ET | 463 | 15.175 |
10:12 ET | 5354 | 15.12 |
10:14 ET | 831 | 15.04 |
10:15 ET | 3916 | 14.9425 |
10:17 ET | 925 | 14.945 |
10:19 ET | 500 | 14.98 |
10:21 ET | 474 | 14.93 |
10:24 ET | 11466 | 14.99 |
10:26 ET | 21576 | 14.92 |
10:28 ET | 2850 | 14.81 |
10:30 ET | 300 | 14.83 |
10:32 ET | 793 | 14.75 |
10:33 ET | 10031 | 14.71 |
10:35 ET | 1833 | 14.67 |
10:37 ET | 2338 | 14.685 |
10:39 ET | 739 | 14.69 |
10:42 ET | 5661 | 14.67 |
10:44 ET | 2622 | 14.695 |
10:46 ET | 6669 | 14.78 |
10:48 ET | 855 | 14.84 |
10:50 ET | 1006 | 14.77 |
10:51 ET | 800 | 14.71 |
10:53 ET | 1445 | 14.78 |
11:00 ET | 600 | 14.79 |
11:02 ET | 300 | 14.775 |
11:04 ET | 500 | 14.72 |
11:06 ET | 2800 | 14.75 |
11:08 ET | 100 | 14.75 |
11:09 ET | 300 | 14.8 |
11:11 ET | 100 | 14.8 |
11:15 ET | 1500 | 14.745 |
11:18 ET | 600 | 14.75 |
11:20 ET | 3578 | 14.87 |
11:22 ET | 1864 | 14.9 |
11:26 ET | 400 | 14.94 |
11:29 ET | 1400 | 14.995 |
11:31 ET | 100 | 15.02 |
11:33 ET | 500 | 15.02 |
11:36 ET | 1352 | 14.98 |
11:38 ET | 800 | 15 |
11:40 ET | 540 | 15.1 |
11:42 ET | 1300 | 15.085 |
11:44 ET | 1100 | 15.09 |
11:45 ET | 200 | 15.11 |
11:47 ET | 2343 | 15.035 |
11:49 ET | 14600 | 15.255 |
11:51 ET | 1567 | 15.2 |
11:54 ET | 400 | 15.215 |
11:56 ET | 200 | 15.24 |
11:58 ET | 1000 | 15.165 |
12:00 ET | 100 | 15.2 |
12:02 ET | 1957 | 15.095 |
12:03 ET | 2913 | 15.1 |
12:05 ET | 300 | 15.085 |
12:07 ET | 400 | 15.08 |
12:09 ET | 100 | 15.08 |
12:12 ET | 200 | 15.085 |
12:14 ET | 2511 | 15.07 |
12:16 ET | 19050 | 15.105 |
12:18 ET | 969 | 15.09 |
12:20 ET | 3992 | 15.16 |
12:23 ET | 400 | 15.2 |
12:25 ET | 1909 | 15.22 |
12:27 ET | 508 | 15.2299 |
12:30 ET | 600 | 15.19 |
12:32 ET | 200 | 15.23 |
12:34 ET | 447 | 15.23 |
12:36 ET | 962 | 15.2 |
12:38 ET | 100 | 15.21 |
12:39 ET | 100 | 15.21 |
12:41 ET | 300 | 15.2 |
12:43 ET | 200 | 15.21 |
12:45 ET | 200 | 15.23 |
12:48 ET | 2950 | 15.22 |
12:50 ET | 100 | 15.215 |
12:52 ET | 1419 | 15.2175 |
12:56 ET | 2600 | 15.225 |
12:57 ET | 1036 | 15.2 |
12:59 ET | 3968 | 15.32 |
01:06 ET | 900 | 15.32 |
01:08 ET | 1165 | 15.25 |
01:10 ET | 663 | 15.24 |
01:12 ET | 100 | 15.235 |
01:14 ET | 300 | 15.255 |
01:15 ET | 200 | 15.245 |
01:17 ET | 100 | 15.23 |
01:19 ET | 300 | 15.23 |
01:21 ET | 300 | 15.24 |
01:24 ET | 200 | 15.235 |
01:26 ET | 466 | 15.235 |
01:28 ET | 561 | 15.24 |
01:30 ET | 1300 | 15.25 |
01:32 ET | 3559 | 15.27 |
01:33 ET | 500 | 15.23 |
01:35 ET | 4915 | 15.08 |
01:37 ET | 100 | 15.065 |
01:39 ET | 100 | 15.065 |
01:42 ET | 300 | 15.07 |
01:44 ET | 100 | 15.07 |
01:46 ET | 2307 | 15.14 |
01:48 ET | 200 | 15.1025 |
01:50 ET | 100 | 15.105 |
01:51 ET | 200 | 15.105 |
01:53 ET | 100 | 15.105 |
01:55 ET | 300 | 15.115 |
01:57 ET | 800 | 15.09 |
02:00 ET | 200 | 15.095 |
02:02 ET | 100 | 15.09 |
02:04 ET | 300 | 15.09 |
02:06 ET | 100 | 15.09 |
02:08 ET | 100 | 15.09 |
02:09 ET | 747 | 15.12 |
02:11 ET | 100 | 15.09 |
02:15 ET | 1165 | 15.12 |
02:18 ET | 300 | 15.125 |
02:20 ET | 1160 | 15.1 |
02:22 ET | 1000 | 15.08 |
02:24 ET | 543 | 15.08 |
02:26 ET | 145 | 15.08 |
02:27 ET | 200 | 15.09 |
02:29 ET | 246 | 15.08 |
02:31 ET | 2992 | 15.11 |
02:33 ET | 100 | 15.105 |
02:36 ET | 2813 | 15.1 |
02:38 ET | 200 | 15.09 |
02:40 ET | 200 | 15.09 |
02:42 ET | 4173 | 15.11 |
02:44 ET | 500 | 15.14 |
02:45 ET | 200 | 15.14 |
02:47 ET | 200 | 15.14 |
02:49 ET | 500 | 15.14 |
02:51 ET | 3094 | 15.205 |
02:54 ET | 111 | 15.205 |
02:56 ET | 791 | 15.21 |
02:58 ET | 100 | 15.21 |
03:00 ET | 876 | 15.26 |
03:02 ET | 373 | 15.255 |
03:03 ET | 200 | 15.255 |
03:05 ET | 1705 | 15.23 |
03:07 ET | 1139 | 15.235 |
03:09 ET | 977 | 15.245 |
03:12 ET | 300 | 15.26 |
03:14 ET | 981 | 15.28 |
03:16 ET | 3671 | 15.25 |
03:18 ET | 132 | 15.27 |
03:20 ET | 300 | 15.275 |
03:21 ET | 503 | 15.28 |
03:23 ET | 900 | 15.295 |
03:25 ET | 633 | 15.325 |
03:27 ET | 2594 | 15.34 |
03:30 ET | 200 | 15.33 |
03:32 ET | 642 | 15.25 |
03:34 ET | 807 | 15.275 |
03:36 ET | 535 | 15.28 |
03:38 ET | 653 | 15.285 |
03:39 ET | 3939 | 15.37 |
03:41 ET | 213 | 15.4 |
03:43 ET | 1400 | 15.38 |
03:45 ET | 2277 | 15.41 |
03:48 ET | 1186 | 15.41 |
03:50 ET | 3010 | 15.36 |
03:52 ET | 11167 | 15.47 |
03:54 ET | 7229 | 15.41 |
03:56 ET | 3822 | 15.415 |
03:57 ET | 21088 | 15.4316 |
03:59 ET | 96197 | 15.43 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Olema Pharmaceuticals Inc | 821.7M | -7.7x | --- |
Rapport Therapeutics Inc | 812.4M | -15.9x | --- |
CARGO Therapeutics Inc | 811.5M | -6.1x | --- |
Dianthus Therapeutics Inc | 824.4M | -9.1x | --- |
Lexicon Pharmaceuticals Inc | 842.2M | -2.9x | --- |
Erasca Inc | 778.2M | -3.9x | --- |
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The Company's OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including ESR1 and PIK3CA mutations and central nervous system (CNS), metastasis. It is in the Phase I/ II clinical trial, and in Phase Ib/ II combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $821.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 55.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.00 |
EPS | $-2.02 |
Book Value | $4.62 |
P/E Ratio | -7.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.